May 17, 2024, 11:41
Sara Tolaney: Helpful discussion by Cristina Saura on how to think about adjuvant therapies in patients with gBRCAm
Sara Tolaney shared a post on X:
“Very helpful discussion by Cristina Saura on how to think about adjuvant therapies in patients with gBRCAm.
Could we consider sequential adjuvant abemaciclib after olaparib in high-risk pts with ER and BC and gBRCAm?”
Source: Sara Tolaney/X
Sara Tolaney is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute. She also serves as Associate Director of the Susan F. Smith Center for Women’s Cancers and is a Senior Physician at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School.
Her research focuses on the development of novel therapies in the treatment of breast cancer and developing more effective and less toxic treatment approaches.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 14:06
Dec 21, 2024, 13:46
Dec 21, 2024, 13:40
Dec 21, 2024, 13:33